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Background: The outcome of patients with nasopharyngeal carcinoma (NPC) presenting as advanced-stage
disease or failing conventional radio-chemotherapy is poor. Thus, additional forms of effective, low-toxicity
treatment are warranted to improve NPC prognosis. Since NPC is almost universally associated with Epstein–
Barr virus (EBV), cellular immunotherapy with EBV-specific cytotoxic T lymphocytes (CTLs) may prove a
successful treatment strategy.
Patient and methods: A patient with relapsed NPC, refractory to conventional treatments, received salvage
adoptive immunotherapy with EBV-specific CTLs reactivated ex vivo from a human leukocyte antigen-identical
sibling. EBV-specific immunity, as well as T-cell repertoire in the tumor, before and after immunotherapy, was
evaluated.
Results: CTL transfer was well tolerated, and a temporary stabilization of disease was obtained. Moreover,
notwithstanding the short in-vivo duration of allogeneic CTLs, immunotherapy induced a marked increase of
endogenous tumor-infiltrating CD8+ T lymphocytes, and a long-term increase of latent membrane protein
2-specific immunity.
Conclusions: Preliminary data obtained in this patient indicate that EBV-specific CTLs are safe, may exert
specific killing of NPC tumor cells in vitro, and induce antitumor effect in vivo.
Key words: cellular immunotherapy, cytotoxic T lymphocytes, Epstein–Barr virus, latent membrane 
protein 2, nasopharyngeal carcinoma
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most important
epithelial neoplasms in world health terms. Currently, the elective
form of treatment for NPC is combined radiotherapy and chemo-
therapy, which cures 80–90% of cases presenting with early stage
tumor [1, 2]. However, the outcome of patients with advanced
stage disease at diagnosis or relapsing after first-line therapy is
poor [1, 2]. Thus, additional forms of effective, low-toxicity treat-
ment are warranted.
NPC is almost universally associated with Epstein–Barr virus
(EBV), which is present in tumor cells in a latency II state, charac-
terized by the expression of a restricted number of viral proteins,
with latent membrane protein (LMP)1 and LMP2 as the only
immunogenic antigens [3]. Recent work has shown that NPC cells
are capable of immunological processing for cytotoxic T-lympho-
cyte (CTL) recognition [4, 5]. Based on these data, and on the
encouraging results obtained by cellular immunotherapy with
EBV-specific CTL lines in the prevention and treatment of
the latency III, EBV-related post-transplant lymphoproliferative
disease [6, 7], pilot trials of cellular immunotherapy for other
EBV-associated cancers have been conducted [8, 9].
However, so far there is no evidence that EBV-specific CTLs
reactivated from NPC patients are capable of lysing autologous
tumor cells in vitro and mediating tumor killing in vivo. An
increase in EBV-specific CTL precursor (CTLp) frequency was
observed after infusion of autologous virus-specific CTLs in four
patients with NPC, but no data on in vitro anti-tumor activity were
available, and no clinical benefit could be observed [9].
We describe the case of a NPC patient who received EBV-
specific CTLs reactivated from a human leukocyte antigen
(HLA)-matched family donor, which showed in vitro cytotoxicity
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towards the patient’s tumor cells, and, once transferred in vivo,
induced temporary stabilization of disease and enhancement of
the patient’s EBV–LMP2-specific T-cell responses.
Study design
Patient
A 40-year-old Caucasian male was diagnosed to have stage IIB, EBV-positive
NPC in 1989. He received cisplatin/5-fluorouracil chemotherapy and radio-
therapy on the primary tumor and cervical nodes, achieving complete remission
(CR). In 1997 local recurrence was documented, and the patient achieved a
second CR after bleomycin, methotrexate and cisplatin chemotherapy plus
brachytherapy. In August 1999, the disease relapsed locally and to the cervical
nodes. He received cisplatin/5-fluorouracil therapy and subsequently pacli-
taxel, with no response. In October 2000 the patient presented with nasal
obstruction and impairment of cranial nerves II and IV, due to bulky NPC pro-
gression infiltrating the skull base and the cavernous sinuses. Since no response
was observed after fourth-line cisplatin–doxorubicin chemotherapy, we elected
to give salvage adoptive immunotherapy with EBV-specific CTLs reactivated
from a HLA-identical sibling.
Approval for this study was obtained from the Institutional Review Board,
and both donor and patient gave written informed consent before enrolment.
EBV-specific CTL expansion and administration
EBV-specific CTLs were reactivated and expanded in vitro according to a
method previously reported, following good laboratory practice standard pro-
cedures [7]. In brief, EBV-specific CTLs were prepared from fresh or frozen
peripheral blood mononuclear cells (PBMCs), plated in 2 ml X-VIVO 20 medium
(BioWhittaker, Walkersville, MD, USA) with 2% autologous plasma, at 2 × 106
cells per well and stimulated with irradiated autologous B-lymphoblastoid cell
line (LCL) at a responder-to-stimulator (R:S) ratio of 40:1. After 10 days, cul-
tures were restimulated with irradiated autologous B-LCL at a R:S ratio of 4:1.
Starting on day 14, 20 U/ml recombinant interleukin-2 (rIL-2; Hoffman-
La Roche, Basel, Switzerland) were added to the wells, and the cultures were
subsequently restimulated weekly with irradiated autologous B-LCL in the
presence of rIL-2.
Before cryopreservation, T cells were examined for immunophenotype,
sterility and EBV specificity in a standard 51Cr-release assay against a panel of
targets including donor B-LCL, recipient EBER+ tumor cells, and recipient
phytohemagglutinin (PHA) blasts. Tumor cells were obtained from a baseline
tumor biopsy, after seeding tumor sections overnight in a culture flask in a
small volume of IMDM (Gibco, Grand Island, NY, USA) supplemented with
20% fetal calf serum (FCS; Sigma, St Louis, MO, USA). Adherent cells were
maintained with weekly passages in IMDM–FCS medium, until a substantial
outgrowth of cells was observed, and then analyzed for immunophenotype and
EBER expression. Early-passage neoplastic cells were used to minimize the
possibility of loosing primary characteristics as a consequence of extensive
in vitro re-culturing.
CTL infusion schedule included a first dose of 2 × 107 CTL/m2, and
3-weekly subsequent doses of 4 × 107 CTL/m2.
Analysis of CTL presence and persistence at the tumor site
Presence and persistence of infused CTLs of donor origin was monitored
through T-cell receptor repertoire analysis by CDR3 spectratyping. In detail,
CDR3 size length analysis was employed to characterize T-cell clonotypes on
donor EBV-specific CTLs, lymphocytes derived from tumor site tissue before
and after cell therapy, and on the peripheral blood of patients after CTL infu-
sion, according to a previously described method [10].
Evaluation of specific immunity
EBV- and LMP2-specific immunity before and after immunotherapy was evalu-
ated by limiting dilution analysis of CTLp [7], by measuring the frequency of
IFNγ-secreting cells in a ELISPOT assay [11], and by reactivation of specific
CTLs.
In detail, to evaluate CTLp frequency to EBV, responder cells were stimu-
lated with autologous irradiated B-LCL in a limiting dilution assay. Briefly,
24 replicates of decreasing numbers (8 × 104, 6 × 104, 4 × 104, 2 × 104, 104, 5 × 103,
2.5 × 103) of cryopreserved PBMCs, used as responder cells, were seeded in
96-well round-bottom microplates in a final volume of 200 µl RPMI (Gibco)–
FCS medium in the presence of 104 autologous irradiated (7000 rads) B-LCL.
On days 7 and 14, the cultures were restimulated with 104 autologous irradi-
ated B-LCL. On day 21, the plates were split and tested against autologous or
HLA-mismatched B-LCL in a standard cytotoxicity assay. For ELISPOT
assay, 96-well multiscreen filter plates (MAIPS 4510; Millipore, Bedford,
MA, USA) were coated with 100 µl of primary antibody (IFNγ; Mabtech,
Nacka, Sweden) at 2.5 µg/ml, and incubated overnight at 4°C. PBMCs were
thawed and cultured overnight in RPMI–FCS medium before use in the assay,
and were then seeded in the absence or in the presence of peripheral blood
monocyte-derived dendritic cells (DC) pulsed with vaccinia-LMP2. Controls
included wells plated with vaccinia-βgal-pulsed DC. After incubation for 24 h
at 37°C, 100 µl of biotinylated secondary antibody (Mabtech; 0.5 µg/ml) was
added, and plates were then processed according to standard procedure. IFNγ-
producing spots were counted using a Elispot reader (Bioline, Torino, Italy).
The number of spots per well was calculated after subtraction of assay back-
ground, quantitated as the average of 24 wells containing only sterile complete
medium, and specific background, quantitated as the sum of cytokine spots
associated with responders alone, and responders plated with vaccinia-βgal-
pulsed DC.
Tumor-infiltrating lymphocytes were obtained by culturing phosphate-
buffered saline-washed tumor sections in RPMI–FCS medium containing IL-2
(100 IU/ml). Medium was replaced on day +6, and on day +10 cells were
harvested, phenotyped and used fresh or cryopreserved.
Results and discussion
At the time of enrolment, expansion of the patient’s EBV-specific
CTLs was attempted, but due to poor CTL growth rate, total cell
yield was insufficient for T-cell therapy. Thus, an EBV-specific
CTL line was successfully expanded from the patient’s HLA-
matched sibling, which, in addition to strong lysis of autologous
B-LCL, showed cytotoxicity against the patient’s NPC cells in the
absence of lysis toward the patient’s PHA blasts. Phenotype and
functional characteristics of donor CTLs are reported in Figure 1.
Allogeneic EBV-specific CTL infusions were well tolerated. A
temporary appearance of symptoms due to cranial nerves II and
IV impairment, likely due to an initial homing of infused CTLs in
the tumor, was observed after the first infusion and resolved spon-
taneously. Notwithstanding the progressing, large tumor bulk at
the time of immunotherapy, a CT scan performed 1 week after
the fourth CTL infusion revealed a minimal reduction of the
intracranial portion of the tumor, that after a 3-month stabilization,
progressed.
Tumor biopsies were performed before and 2 weeks after com-
pletion of CTL infusion schedule. Immunohistochemical staining
showed a marked increase of CD8+ lymphocytes in the tumor
after CTL therapy (data not shown). We proceeded to analyze the
T-cell repertoire, and found that a marked increase of the message
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for T-cell repertoire was present after the CTL infusion (Figure 2).
Moreover, the repertoire was found to be identical, as for CDR3
length, before and after CTL infusion, but different to the infused
CTLs (Figure 2B). To better characterize these T cells, we sequenced
some of the BV families found to be more expanded. The results
concerning BV18 (Figure 2C) show the same prominent peak
before and after infusion, and a 3bp shorter peak in the CTLs. The
sequencing data revealed that the same clone was found before
and after infusion, and no sequence motif was found in the CDR 3
region of the same family in the CTLs, suggesting that donor
CTLs were not present at the time of the analysis.
We then assessed whether infusion of allogeneic EBV-specific
CTLs had any effect on the patient’s specific immunity. In partic-
ular, we analyzed the frequency of EBV LCL-specific and LMP2-
specific CTLp and IFNγ-secreting cells, together with specific
cytotoxic activity of CTL lines reactivated from the patient before
and after CTL infusion (Figure 3A and B). The frequency of CTLp
and IFNγ-secreting cells directed towards EBV LCL, which was
in the range reported for EBV-positive healthy individuals [11]
before infusion, was found to be only slightly increased after CTL
treatment, likely reflecting an initial increase followed by rapid
reduction upon development of reactivity towards the allogeneic
T cells (Figure 3B). However, the frequency of LMP2-specific
CTLp and IFNγ-secreting cells, which was very low or undetect-
able before CTL administration, increased after cell therapy, reach-
ing values observed in healthy EBV-seropositive controls [11].
Thus, whereas no substantial long-term difference could be observed
in specific immunity toward EBV LCL, a measurable increase of
LMP2-directed responses was detected after CTL infusions,
which translated into a stronger LMP2-specific component in
EBV-specific CTLs reactivated from the patient after allogeneic
CTL infusion (Figure 3A). Since CDR3 length analysis performed
Figure 1. Characteristics of the transferred allogeneic Epstein–Barr virus 
(EBV)-specific cytotoxic T-lymphocytes (CTL) line. Cytotoxicity and 
phenotype features of donor EBV-specific CTLs are shown. EBV- and 
tumor-specificity of the cultured T cells is demonstrated by sizeable lysis of 
autologous EBV B-lymphoblastoid cell line (B-LCL; white bar) and 
patient’s tumor cells (third bar), in the absence of cytotoxicity against 
patient’s phytohemagglutinin (PHA) blasts (fifth bar). Human leukocyte 
antigen (HLA)-restriction is proved by prevention of specific lysis in the 
presence of anti-HLA class I monoclonal antibody (clone W6/32; Dako, 
Glostrup, Denmark) (black bar). Cytotoxicity against vaccinia-latent 
membrane protein (LMP)2-pulsed dendritic cells (DC) is also reported 
(fourth bar). Spontaneous chromium release was always <20% for all target 
cells. Data represent cytotoxicity at a 5:1 effector-to-target (E:T) ratio, and 
are the mean of triplicate wells.
Figure 2. T-cell repertoire (TCR) analysis on tumor tissue before and after 
T-cell therapy. (A) The analysis for five representative BV families (BV1, 
BV4, BV15, BV18, BV 24), before (empty bar) and after (black bar) 
cytotoxic T-lymphocyte (CTL) infusion. (B) The TCR analysis for 13 BV 
families. Families BV19 and BV10 were not shown because these are 
pseudogenes, the TCR-BV families 3, 5.1, 5.3, 7, 8, 12, 20, 25 showed a 
normal, Gaussian-like, distribution. The arrow indicates the BV families 
found to have a prominent peak before and after CTL infusion. The 
sequence of these peaks showed that they had the same sequence at both 
nucleotidic and amino acid level (data not shown). The asterisks indicate 
the TCR-BV18 family whose sequence is shown in (C). BV and BJ identify 
the gene families.
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on the patient’s PBMCs obtained 2 months after the fourth CTL
infusion (data not shown) did not reveal the presence of donor-
derived expanded clones in the peripheral blood, and, more
importantly, no donor cells were found at the tumor site 2 weeks
after the fourth infusion, we assume that donor T cells were absent
from the patient’s peripheral blood at the time of immunological
analysis. Thus, the increase in LMP2-specific responses is likely
ascribable to a patient’s T cells. The boosting effect of donor T-cell
infusions on patient’s immune response may have been due to
both a bystander activation and a direct cytotoxic effect of the
CTLs, which induced a release of tumor antigens. Since EBNA3
antigens, the dominant target of EBV LCL-induced CTL responses,
are not present in NPC tumor cells, no boosting of the patient’s
EBV LCL-directed response could be observed.
Since donor CTL infusion was almost immediately followed by
the appearance of symptoms suggestive of CTL trafficking to
tumor site, it is reasonable to hypothesize that infused CTLs were
responsible for the tumor’s reduction, but were no longer present
when the second biopsy was taken. Indeed, as recently demon-
strated by Yee et al., autologous CD8+ T-cell clones infused in
patients with melanoma persisted for a median of 7 days after
transfer, in the absence of systemically delivered IL-2 [12]. In our
case, although CTLs included CD4+ T cells, known to provide
‘help’ for antigen-specific CD8+ T-cell persistence, the half-life
was likely reduced due to the allogeneic setting. Notwithstanding
the increased endogenous anti-LMP2 immunity, and the aug-
mented number of CD8+ cells in the tumor, the clinical response
in our patient was transient. This might be due to reduced donor
CTL persistence, associated to a low activity towards autologous
tumor cells and EBV LCL exerted by tumor-infiltrating lympho-
cytes of patient origin (Figure 3A), in comparison with donor
CTLs. Moreover, treatment-induced selection for antigen-loss
variants may also have played a role.
Preliminary data obtained in this patient indicate that EBV-
specific CTLs are able to exert specific killing of patients’ NPC
cells in vitro, can be used safely, and may show antitumor effect
in vivo. Given the short in vivo duration of allogeneic CTLs,
immunotherapy of NPC may be implemented by the use of autol-
ogous EBV-specific CTLs [13, 14]. Recently, it has been reported
that immunization with LMP2 peptide-pulsed autologous DCs
boosted epitope-specific T-cell responses in NPC patients, induc-
ing partial clinical responses in selected patients [15]. Thus, to
improve antitumor response, LMP2 and/or LMP1-specific CTLs
[16, 17] could be employed, supported by low-dose IL-2 adminis-
tration [12].
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